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Drug demand reduction: global evidence for local actions
The development of evidence‑based 
demand reduction interventions is 
a primary drug policy objective at 
national, European Union (EU) and 
global level. A particular discourse, 
with its own set of concepts, is used 
to discuss implementation of this 
objective, including terms such as: 
best practice, quality standards, 
guidelines, protocols, accreditation 
systems and benchmarking. 
This paper provides readers with 
straightforward definitions of the 
terms used, whilst highlighting 
achievements and current challenges 
in transferring scientific knowledge 
into practice in the drug demand 
reduction arena. A special focus 
is given to ‘best practice’ because 
of this concept’s increasing popularity 
and importance in Europe.
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Definitions
Best practice: the best application of the available evidence to current activities.
Evidence base: a concept imported from the medical field, defined as ’the conscientious, explicit, and judicious use of current best evidence in 
making decisions about the care of individual patients’ (Sackett, 1996). When applied to drug demand reduction, this refers to the use of scientific 
results to inform interventions decisions.
Guidelines: ‘statements that include recommendations intended to optimise patient care that are informed by a systematic review of evidence 
and an assessment of the benefits and harms of alternative care options’ (Institute of Medicine, 2011).
Protocols: documents that specify the procedures to follow for the performance of certain tasks.
Standards and quality standards: principles and sets of rules based on evidence (Brunsson and Jacobsson, 2000), used to implement 
the interventions recommended in guidelines. They can refer to content issues, processes, or to structural aspects.
Accreditation: the process by which an institution delivering a service is independently assessed for quality against pre‑defined criteria and 
standards, which are set by the accrediting body.
Benchmarking: the process of comparing service processes and performance to best practices from other services. Dimensions typically 
measured are quality, time and cost.
Key issues at a glance
1. The promotion and exchange of best practice is recognised as an 
important strategy both to improve the effectiveness of 
drug‑related interventions and ensure the efficient use of limited 
resources.
4. At European level, a recent project has aimed to promote consensus on 
minimum quality standards in the fields of drug prevention, treatment 
and harm reduction as well as the translation of quality standards into 
practice.
2. Guidelines and standards are among the most frequently used 
tools for the promotion of best practice. In Europe, a wealth of 
guidelines now exist which decision‑makers can utilise, update 
and adapt to suit their own national contexts, rather than starting 
from scratch.
5. New disciplines have emerged focusing on methods for successful 
transfer, such as implementation science, translational science, and 
knowledge mobilisation. Identification of barriers to change and use of 
multiple implementation strategies are important success factors.
3. There is a growing body of scientific evidence on the effectiveness 
of interventions in the drugs field, which can be used for the 
development and update of standards and guidelines. There is 
new emphasis on disinvestment, stopping ‘poor practice’ and the 
use of low quality interventions.
6. In the best practice area, there are still many gaps in the scientific 
evidence base and new issues continually arise that need to be 
addressed. A systematic gap analysis will help to focus next steps and 
future developments.
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1. Understanding 
best practice
A definition of the ’best practice’ 
concept was recently developed by 
a group of European experts convened 
by the EMCDDA. In brief, best practice 
is the best application of the available 
evidence to current activities in the drugs 
field. A number of factors were identified 
as contributing to making an intervention 
qualify as ’best practice’. In summary, 
a best practice intervention is based 
on the most robust scientific evidence 
available regarding what is known to 
be effective in producing successful 
outcomes, and it is tailored to the needs 
of those it addresses. Methods used 
will be transparent, reliable and 
transferable and can be updated as 
the knowledge base develops. With 
regard to implementation, local 
contextual factors will be taken into 
account and the intervention will be 
harmonised with other actions as 
a part of a comprehensive approach 
to drug problems.
Best practice is closely linked to the 
concept of ’evidence‑based practice’ 
— the conscientious, explicit and 
judicious use of current best evidence in 
making decisions (Sackett et al.,1996), 
and it requires the careful integration 
of both scientific knowledge and 
implementation expertise in order to 
appropriately adapt the intervention to 
the single individual and/or to a specific 
context. A best practice intervention 
should provide better outcomes than 
other interventions and therefore also 
allow a rational allocation of resources.
2. Guidelines and standards: 
popular instruments to 
promote best practice
The most common strategy in Europe 
to promote best practice is the 
development of guidelines and 
standards. By 2011, over 143 sets of 
drug treatment guidelines had been 
identified across the region, many of 
them in the area of opioid substitution 
treatment. In many cases, the process 
of drafting new guidelines or standards 
now relies on using existing national 
examples (provided they are based on 
evidence) and adapting them to the 
local context, hence saving resources. 
An inventory of national guidelines and 
standards in treatment, prevention and 
harm reduction is available on the 
EMCDDA’s Best practice portal at the 
following address: http://www.emcdda.
europa.eu/best‑practice.
There remain challenges associated with 
the promotion of best practice through 
guidelines, standards and other similar 
tools. The first is to make sure that they 
are based on reliable scientific evidence 
and that they are regularly updated 
when new systematic reviews are 
published. The second is to make best 
use of the currently existing guidelines in 
Europe. Finally, it is important to ensure 
that guidelines and standards are 
appropriately implemented.
3. Accessing and using 
scientific evidence
The number of studies on the 
effectiveness of drug‑related 
interventions has multiplied over the last 
fifty years and created a need for high 
quality synthesis. At the end of the 
1990s an editorial group on drugs 
and alcohol was created within 
the Cochrane Collaboration (an 
international not‑for‑profit organisation 
preparing, maintaining and promoting 
the accessibility of systematic reviews of 
the effects of healthcare). This Cochrane 
Group of Drugs and Alcohol aims to 
produce and disseminate systematic 
reviews of trials on the prevention, 
treatment and rehabilitation of the 
problematic use of drugs and alcohol. 
To this day the group collaborates 
with the EMCDDA’s Best practice portal 
to synthesise available evidence 
on interventions. 
The current financial climate requires all 
decision‑makers to find ways of 
controlling costs without cutting quality 
of care. In addition to being used for the 
identification of effective interventions, 
the scientific evidence base is 
increasingly being cited in order to 
reduce or terminate the use of poor 
quality approaches and services. The 
National Institute for Clinical Excellence 
(NICE) in the United Kingdom has 
implemented so‑called ’disinvestment’ 
processes to stop the funding of ‘low 
value’ clinical interventions — for 
example, because they are not clinically 
effective, have a poor risk‑benefit profile, 
or are not supported by adequate 
evidence. This involves withdrawing 
health resources from existing healthcare 
practices that are deemed to deliver 
little or no health gain for their cost, 
and thus do not represent an efficient 
use of resources. 
4. Learning from each 
other — minimum quality 
standards for Europe
While each European country has 
developed its own strategy and 
responses to drug problems, taking into 
account the size of its drug problem 
and available resources, there is a clear 
benefit in sharing experiences and 
lessons learned with other countries, 
helping to develop quality improvements 
and effectiveness research. European 
level minimum quality standards need 
to add value to what exists within 
individual Member States and take 
account of different health systems and 
capacities across countries.
‘All interventions are well 
intentioned but not all 
interventions are equally effective. 
Today more than ever, we need 
to ensure we invest in what works 
and disinvest in what does not. To 
achieve this, we need not only 
a common understanding of the 
evidence base for effectiveness 
but also guidelines to inform 




A recent EU‑funded project has been 
developing European Minimum Quality 
Standards (EQUS) for drug prevention, 
treatment and harm reduction, by 
convening experts and stakeholders 
from Europe and beyond, in order 
to propose lists of minimum standards 
based on evidence and consensus. 
European drug prevention quality 
standards have been adapted to form 
the prevention strand of the study and 
these were published in December 2011 
by the EMCDDA in its Manuals series, 
and are available for download and 
to order for free from the EMCDDA 
website at http://www.emcdda.europa.
eu/publications/manuals/
prevention‑standards. The results from 
the EQUS study will be further 
developed by the European Commission 
in order to prepare a draft proposal 
to be submitted to the Council of the 
European Union.
5. Implementing evidence 
through guidelines, 
standards and other tools
The successful transfer of evidence 
into practice via guidelines and 
standards requires both planning 
and a proactive approach. A broad 
range of activities are used to 
translate evidence into action, and 
several new scientific disciplines have 
arisen which directly address this 
topic, for example: translational 
science, knowledge translation, and 
knowledge mobilisation. For many 
of these approaches, the relationship 
between scientific evidence and 
expert consensus is central to the 
implementation process. For 
successful implementation, expert 
consensus is crucial to identify 
relevant questions, to adapt 
recommendations to the local context, 
and to ensure interventions are 
appropriately structured and tailored 
to the target group. While national 
approaches can differ, the identification 
of so‑called ’barriers to change’ in 
the target group, and active moves 
to minimise these barriers, can enhance 
take‑up of new interventions. Also 
the use of incentives such as training, 
accreditation or certification, can 
support the successful implementation 
of quality standards in drug 
demand reduction.
6. Next steps: identifying 
gaps and considering 
new issues
Developments in drug‑related research 
and in evidence‑based practices 
have resulted in the creation of new 
instruments to increase the effectiveness 
of Europe’s response to drug problems. 
This process has, however, also revealed 
significant gaps in the available scientific 
knowledge, and it is evident that 
guidelines or standards have not always 
been developed in an appropriate way 
to promote best practice. In addition, 
changes in the drug situation, for 
example related to an ageing cohort 
of opioid users or to the use of new 
substances, may now require additional 
research and guidance. The EMCDDA 
and its partners are committed to 
conduct a gap analysis in the best 
practice area, and to actively support 
the linking of global knowledge with 
local practices in Europe, whether 
through proactive dissemination 
of evidence, support in guidelines 
adaptation, or fostering impact 
assessment and exchange 
of experiences.
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Conclusions and policy considerations
1. Over the last two decades, Europe has witnessed increasing interest in 
the development and promotion of best practice. Different tools are used 
to promote evidence-based practices in drug demand interventions, such 
as guidelines and quality standards. Nationally, dissemination and 
adaptation of already existing evidence‑based guidelines, rather than 
developing new ones, is proving to be a cost effective solution that helps 
to ensure quality. At European level, a process to promote consensus on 
common minimal quality standards has recently been established.
2. In the future, processes need to be in place to ensure that existing 
guidelines and standards are regularly updated as and when new 
evidence becomes available. In addition, the ongoing promotion and 
dissemination of guidelines and standards among professionals and 
decision-makers is a key issue. Despite recent increases in the availability 
of scientific evidence on the effectiveness (and ineffectiveness) of 
drug‑related interventions, gaps still exist and research is required to 
fill these gaps. A European research agenda which gives priority 
to questions linked to both the effectiveness of interventions, and to 
improving the research-practice interface, would be greatly welcomed.
3. The EMCDDA with its experience in monitoring and disseminating best 
practice will continue to promote and support quality improvement in the 
European drugs field. Proactive dissemination of evidence, mentoring 
of guidelines adaptation, support in goal setting and impact evaluation 
and fostering the exchange of experiences are some of the activities we 
will continue to provide to stakeholders.
